Citations for
1HRAS, KRAS, LZTR1, MRAS, NRAS
LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases.
Abe T, Umeki I, Kanno SI, Inoue SI, Niihori T, Aoki Y.
Cell Death Differ. Mar;27(3):1023-1035. doi: 10.1038/s41418-019-0395-5. Epub 2019 Jul 23 2020
2HK1, KRAS
KRAS4A directly regulates hexokinase 1.
Amendola CR, Mahaffey JP, Parker SJ, Ahearn IM, Chen WC, Zhou M, Court H, Shi J, Mendoza SL, Morten MJ, Rothenberg E, Gottlieb E, Wadghiri YZ, Possemato R, Hubbard SR, Balmain A, Kimmelman AC, Philips MR.
Nature Dec;576(7787):482-486. doi: 10.1038/s41586-019-1832-9. Epub 2019 Dec 11. 2019
3KRAS, SOS2
Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E, Sealover NE, Wang C, Kim DH, Vazirani IA, Lee E, M Terrell E, Morrison DK, Luo J, Kortum RL.
Sci Signal 11(546). pii: eaar8371. doi: 10.1126/scisignal.aar8371. 2018
4HRAS, KRAS, LZTR1
LZTR1 is a regulator of RAS ubiquitination and signaling.
Bigenzahn JW, Collu GM, Kartnig F, Pieraks M, Vladimer GI, Heinz LX, Sedlyarov V, Schischlik F, Fauster A, Rebsamen M, Parapatics K, Blomen VA, Müller AC, Winter GE, Kralovics R, Brummelkamp TR, Mlodzik M, Superti-Furga G.
Science Dec 7;362(6419):1171-1177. doi: 10.1126/science.aap8210. Epub 2018 Nov 15 2018
5AGO2, KRAS
KRAS Engages AGO2 to Enhance Cellular Transformation.
Shankar S, Pitchiaya S, Malik R, Kothari V, Hosono Y, Yocum AK, Gundlapalli H, White Y, Firestone A, Cao X, Dhanasekaran SM, Stuckey JA, Bollag G, Shannon K, Walter NG, Kumar-Sinha C, Chinnaiyan AM.
Cell Rep 14(6):1448-1461. doi: 10.1016/j.celrep.2016.01.034. Epub 2016 Feb 4. 2016
6KRAS, RALA, RALB
Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation.
Tecleab A, Zhang X, Sebti SM.
J Biol Chem 289(45):31296-309. doi: 10.1074/jbc.M114.565796. Epub 2014 Sep 10. 2014
7KRAS, RNF7
Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.
Li H, Tan M, Jia L, Wei D, Zhao Y, Chen G, Xu J, Zhao L, Thomas D, Beer DG, Sun Y.
J Clin Invest. Feb;124(2):835-46. doi: 10.1172/JCI70297. Epub 2014 Jan 16. 2014
8GOT1, KRAS
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.
Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, Kang Y, Fleming JB, Bardeesy N, Asara JM, Haigis MC, DePinho RA, Cantley LC, Kimmelman AC.
Nature 496(7443):101-5. doi: 10.1038/nature12040. Epub 2013 Mar 27. Erratum in: Nature. 2013 Jul 25;499(7459):504. 2013
9CD44, KRAS
CD44 promotes Kras-dependent lung adenocarcinoma.
Zhao P, Damerow MS, Stern P, Liu AH, Sweet-Cordero A, Siziopikou K, Neilson JR, Sharp PA, Cheng C.
Oncogene 32(43):5186-90. doi: 10.1038/onc.2012.542. Epub 2012 Dec 3. 2013
10CFC5, KRAS, NS3
Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes.
Cirstea IC, Gremer L, Dvorsky R, Zhang SC, Piekorz RP, Zenker M, Ahmadian MR.
Hum Mol Genet 22(2):262-70. doi: 10.1093/hmg/dds426. Epub 2012 Oct 11. 2013
11BIRC5, KRAS
Depletion of K-Ras promotes proteasome degradation of survivin.
Tecleab A, Sebti SM.
Cell Cycle 12(3):522-32. doi: 10.4161/cc.23407. Epub 2013 Jan 16. 2013
12CAV1, KRAS
Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis.
Basu Roy UK, Henkhaus RS, Loupakis F, Cremolini C, Gerner EW, Ignatenko NA.
Int J Cancer 133(1):43-57. doi: 10.1002/ijc.28001. Epub 2013 Feb 12. Erratum in: Int J Cancer. 2015 Oct 15;137(8):E18. 2013
13APC, KRAS
Dietary heme iron and the risk of colorectal cancer with specific mutations in KRAS and APC.
Gilsing AM, Fransen F, de Kok TM, Goldbohm AR, Schouten LJ, de Bruďne AP, van Engeland M, van den Brandt PA, de Goeij AF, Weijenberg MP.
Carcinogenesis 34(12):2757-66. doi: 10.1093/carcin/bgt290. Epub 2013 Aug 27. 2013
14HRAS, KRAS
Interplay between oncogenic K-Ras and wild-type H-Ras in Caco2 cell transformation.
Ikonomou G, Kostourou V, Shirasawa S, Sasazuki T, Samiotaki M, Panayotou G.
J Proteomics 75(17):5356-69. doi: 10.1016/j.jprot.2012.06.038. Epub 2012 Jul 16. 2012
15KRAS, MAP3K7
TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.
Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, Haber DA, Settleman J.
Cell 148(4):639-50. doi: 10.1016/j.cell.2011.12.033. 2012
16KRAS, NS1, PTPN11, RASA1
Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
De Rocca Serra-Nédélec A, Edouard T, Tréguer K, Tajan M, Araki T, Dance M, Mus M, Montagner A, Tauber M, Salles JP, Valet P, Neel BG, Raynal P, Yart A.
Proc Natl Acad Sci U S A 109(11):4257-62. doi: 10.1073/pnas.1119803109. Epub 2012 Feb 27. 2012
17KRAS
Regulation of RAS oncogenicity by acetylation.
Yang MH, Nickerson S, Kim ET, Liot C, Laurent G, Spang R, Philips MR, Shan Y, Shaw DE, Bar-Sagi D, Haigis MC, Haigis KM.
Proc Natl Acad Sci U S A 109(27):10843-8. doi: 10.1073/pnas.1201487109. Epub 2012 Jun 18. 2012
18HRAS, KRAS, SMPS1, SMPS2
Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.
Groesser L, Herschberger E, Ruetten A, Ruivenkamp C, Lopriore E, Zutt M, Langmann T, Singer S, Klingseisen L, Schneider-Brachert W, Toll A, Real FX, Landthaler M, Hafner C.
Nat Genet at Genet. 2012 2012
19AXIN2, FOXM1, KRAS
Foxm1 mediates cross talk between Kras/mitogen-activated protein kinase and canonical Wnt pathways during development of respiratory epithelium.
Wang IC, Snyder J, Zhang Y, Lander J, Nakafuku Y, Lin J, Chen G, Kalin TV, Whitsett JA, Kalinichenko VV.
Mol Cell Biol 32(19):3838-50. doi: 10.1128/MCB.00355-12. Epub 2012 Jul 23. 2012
20KRAS
KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis.
Liu X, Jakubowski M, Hunt JL.
Am J Clin Pathol 135(2):245-52. 2011
21CFC5, KRAS, NS3
Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.
Gremer L, Merbitz-Zahradnik T, Dvorsky R, Cirstea IC, Kratz CP, Zenker M, Wittinghofer A, Ahmadian MR.
Hum Mutat 32(1):33-43. doi: 10.1002/humu.21377. Epub 2010 Dec 9. 2011
22KRAS
Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation.
Takagi M, Shinoda K, Piao J, Mitsuiki N, Takagi M, Matsuda K, Muramatsu H, Doisaki S, Nagasawa M, Morio T, Kasahara Y, Koike K, Kojima S, Takao A, Mizutani S.
Blood 117(10):2887-90. Epub 2010 Nov 9. 2011
23KRAS, MYC, NFE2L2
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.
DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA.
Nature 475(7354):106-9. doi: 10.1038/nature10189. 2011
24BRIP1, HRAS, KRAS
Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence.
Tu Z, Aird KM, Bitler BG, Nicodemus JP, Beeharry N, Xia B, Yen TJ, Zhang R.
Dev Cell 21(6):1077-91. doi: 10.1016/j.devcel.2011.10.010. Epub 2011 Dec 1. 2011
25AURKA, KRAS, RASSF5
Growth and tumor suppressor NORE1A is a regulatory node between Ras signaling and microtubule nucleation.
Bee C, Moshnikova A, Mellor CD, Molloy JE, Koryakina Y, Stieglitz B, Khokhlatchev A, Herrmann C.
J Biol Chem 285(21):16258-66. Epub 2010 Mar 25. 2010
26CALM1, KRAS
K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function.
Alvarez-Moya B, López-Alcalá C, Drosten M, Bachs O, Agell N.
Oncogene 29(44):5911-22. Epub 2010 Aug 30. 2010
27KRAS
Multiple cellular proteins modulate the dynamics of K-ras association with the plasma membrane.
Bhagatji P, Leventis R, Rich R, Lin CJ, Silvius JR.
Biophys J 99(10):3327-35. 2010
28KRAS
Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes.
Chun SY, Johnson C, Washburn JG, Cruz-Correa MR, Dang DT, Dang LH.
Mol Cancer 9:293. 2010
29KRAS
Clinical relevance of KRAS in human cancers.
Jancík S, Drábek J, Radzioch D, Hajdúch M.
J Biomed Biotechnol 2010:150960. Epub 2010 Jun 7. Review. 2010
30KRAS
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte Filho JC, Persaud Y, Levine DA, Fagin JA, Jhanwar SC, Mariadason JM, Lash A, Ladanyi M, Saltz LB, Heguy A, Paty PB, Solit DB.
Cancer Res 70(14):5901-11. Epub 2010 Jun 22. 2010
31KRAS
Analysis of k-ras nuclear expression in fibroblasts and mesangial cells.
Fuentes-Calvo I, Blázquez-Medela AM, Santos E, López-Novoa JM, Martínez-Salgado C.
PLoS One 5(1):e8703. 2010
32DUSP4, KRAS, SMYD3
Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas.
Gaedcke J, Grade M, Jung K, Camps J, Jo P, Emons G, Gehoff A, Sax U, Schirmer M, Becker H, Beissbarth T, Ried T, Ghadimi BM.
Genes Chromosomes Cancer 49(11):1024-34. 2010
33KRAS, RPS6KB1, STK33
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Döhner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG.
Cell 137(5):821-34. 2009
34KRAS
Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS.
J Pathol 219(4):435-45. 2009
35KRAS
Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer.
Mlakar V, Berginc G, Volavsek M, Stor Z, Rems M, Glavac D.
BMC Cancer 9:282. 2009
36CALM1, KRAS
The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin.
Abraham SJ, Nolet RP, Calvert RJ, Anderson LM, Gaponenko V.
Biochemistry 48(32):7575-83. 2009
37KRAS
Novel multiple, monoallelic KRAS mutations at codon 12 and 13.
Keller G, Geist B, Slotta-Huspenina J, Langer R, Nagl F, Fend F, Höfler H, Perren A.
Int J Cancer 125(11):2744-5. No abstract available. 2009
38KRAS, MKI67
Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas.
Woo T, Okudela K, Yazawa T, Wada N, Ogawa N, Ishiwa N, Tajiri M, Rino Y, Kitamura H, Masuda M.
Lung Cancer 65(3):355-62. Epub 2009 Jan 21. 2009
39FLT3, NRAS, KRAS, PTPN11
Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
Paulsson K, Horvat A, Stršmbeck B, Nilsson F, Heldrup J, Behrendtz M, Forestier E, Andersson A, Fioretos T, Johansson B.
Genes Chromosomes Cancer 47(1):26-33. 2008
40HRAS, KRAS, BRAF, CFC2, COSTS, CFC3, MAP2K1, MAP2K2, CFC4, CFC5
Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
Schulz AL, Albrecht B, Arici C, van der Burgt I, Buske A, Gillessen-Kaesbach G, Heller R, Horn D, HŸbner CA, Korenke GC, Kšnig R, Kress W, KrŸger G, Meinecke P, MŸcke J, Plecko B, Rossier E, Schinzel A, Schulze A, Seemanova E, Seidel H, Spranger S, Tuysuz B, Uhrig S, Wieczorek D, Kutsche K, Zenker M.
Clin Genet 73(1):62-70. Epub 2007 Nov 27. 2008
41ESX1, KRAS
Anti-tumor activity of ESX1 on cancer cells harboring oncogenic K-ras mutation.
Nakajima J, Ishikawa S, Hamada J, Yanagihara M, Koike T, Hatakeyama M.
Biochem Biophys Res Commun 370(1):189-94. Epub 2008 Mar 24. 2008
42KRAS, NRAS
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.
Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T.
Nat Genet 40(5):600-8. Epub 2008 Mar 30. 2008
43BRAF, CFC2, CFC3, CFC4, CFC5, COSTS, HRAS, KRAS, MAP2K1, MAP2K2, NS3
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y.
Hum Mutat 29(8):992-1006. 2008
44BRAF, CFC2, CFC3, COSTS, HRAS, KRAS, LEOPS, MAP2K1, MAPK1, MTOR, NF1, NFNS, NS1, NS3, NS4, NS5, PTPN11, RAF1, SOS1
Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases.
Krab LC, Goorden SM, Elgersma Y.
Trends Genet 24(10):498-510. Epub 2008 Sep 4. 2008
45HRAS, KRAS, NRAS
Kras and Hras--what is the difference?
Berns A.
Nat Genet 40(10):1149-50. No abstract available. 2008
46CFC3, CFC4, CFC5, KRAS, MAP2K1, MAP2K2, NS3, NS5, RAF1
Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders.
Nyström AM, Ekvall S, Berglund E, Björkqvist M, Braathen G, Duchen K, Enell H, Holmberg E, Holmlund U, Olsson-Engman M, Annerén G, Bondeson ML.
J Med Genet 45(8):500-6. Epub 2008 May 2. 2008
47CFC5, COSTS, HRAS, KRAS, NS3
Clinical and molecular aspects of RAS related disorders.
Denayer E, de Ravel T, Legius E.
J Med Genet 45(11):695-703. Epub 2008 Jun 11. Review. 2008
48KRAS, NS1, NS3, NS4, NS5, PTPN11, RAF1, SOS1
PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome.
Ko JM, Kim JM, Kim GH, Yoo HW.
J Hum Genet 53(11-12):999-1006. Epub 2008 Nov 20. 2008
49KLK6, KRAS
Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells.
Henkhaus RS, Gerner EW, Ignatenko NA.
Biol Chem 389(6):757-64.PMID: 18627290 2008
50NS3, KRAS, COSTS, HRAS
The neoplastic risk in children with Noonan syndrome and Costello syndrome.
Lopez-Rangel E.
Clin Genet 71(1):44-5. 2007
51KRAS, NS3, CFC5
Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations.
Zenker M, Lehmann K, Schulz AL, Barth H, Hansmann D, Koenig R, Korinthenberg R, Kreiss-Nachtsheim M, Meinecke P, Morlot S, Mundlos S, Quante AS, Raskin S, Schnabel D, Wehner LE, Kratz CP, Horn D, Kutsche K.
J Med Genet 44(2):131-5. Epub 2006 Oct 20. 2007
52CFC2, CFC3, CFC4, CFC5, KRAS, MAP2K1, MAP2K2, BRAF, COSTS, HRAS
Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome.
Narumi Y, Aoki Y, Niihori T, Neri G, Cave H, Verloes A, Nava C, Kavamura MI, Okamoto N, Kurosawa K, Hennekam RC, Wilson LC, Gillessen-Kaesbach G, Wieczorek D, Lapunzina P, Ohashi H, Makita Y, Kondo I, Tsuchiya S, Ito E, Sameshima K, Kato K, Kure S, Matsubara Y.
Am J Med Genet A 143(8):799-807. 2007
53KRAS,NS3
Further evidence of genetic heterogeneity in Costello syndrome: involvement of the KRAS gene.
Bertola DR, Pereira AC, Brasil AS, Albano LM, Kim CA, Krieger JE.
J Hum Genet 52(6):521-6. Epub 2007 Apr 28. 2007
54CFC2, BRAF, CFC3, MAP21K1, CFC3, MAP2K2, CFC5, KRAS, COSTS, HRAS
Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T, Aoki Y, Matsubara Y, Arveiler B, Lacombe D, Pasmant E, Parfait B, Baumann C, HŽron D, Sigaudy S, Toutain A, Rio M, Goldenberg A, Leheup B, Verloes A, CavŽ H.
J Med Genet 44(12):763-71. Epub 2007 Aug 17. 2007
55KRAS, BRAF, CFC2
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.
Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Okamoto N, Hennekam RC, Gillessen-Kaesbach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y.
Nat Genet 38(3):294-6. Epub 2006 Feb 12. 2006
56NS3, KRAS
Germline KRAS mutations cause Noonan syndrome.
Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP.
Nat Genet 38(3):331-6. Epub 2006 Feb 12. 2006
57KRAS
Germline Missense Mutations Affecting KRAS Isoform B Are Associated with a Severe Noonan Syndrome Phenotype.
Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, Sarkozy A, Digilio C, Palleschi A, Pizzuti A, Grammatico P, Zampino G, Dallapiccola B, Gelb BD, Tartaglia M.
Am J Hum Genet 79(1):129-35. Epub 2006 May 1. 2006
58KRAS, NCL
K-Ras4B proteins are expressed in the nucleolus: Interaction with nucleolin.
Birchenall-Roberts MC, Fu T, Kim SG, Huang YK, Dambach M, Resau JH, Ruscetti FW.
Biochem Biophys Res Commun 348(2):540-9. Epub 2006 Jul 28. 2006
59KRAS, NRAS
Structural and functional consequences of c-N-Ras constitutively associated with intact mitochondria.
Wolfman JC, Planchon SM, Liao J, Wolfman A.
Biochim Biophys Acta 1763(10):1108-24. Epub 2006 Aug 12. 2006
60BAX, KRAS, MOAP1, RASSF1
The RASSF1A tumor suppressor activates Bax via MOAP-1.
Vos MD, Dallol A, Eckfeld K, Allen NP, Donninger H, Hesson LB, Calvisi D, Latif F, Clark GJ.
J Biol Chem 281(8):4557-63. Epub 2005 Dec 12. 2006
61BRAF, ICMT, KRAS
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf.
Bergo MO, Gavino BJ, Hong C, Beigneux AP, McMahon M, Casey PJ, Young SG.
J Clin Invest 113(4):539-50. 2004
62NRAS, KRAS, HRAS
ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.
Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G.
J Clin Oncol 21(17):3226-35. 2003
63HRAS, KRAS, RCE1
Human Ras converting enzyme endoproteolytic specificity at the P2' and P3' positions of K-Ras-derived peptides.
Hollander IJ, Frommer E, Aulabaugh A, Mallon R.
Biochim Biophys Acta 1649(1):24-9. 2003
64APC, KRAS, TP53, FAP
Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer.
Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, Garner RC, Steele RJ, Wolf CR.
Proc Natl Acad Sci U S A 99(14):9433-8. 2002
65BRAF, KRAS
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.
Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE.
Nature 418(6901):934. 2002
66RASSF1, KRAS
K-ras mutations and RASSF1A promoter methylation in colorectal cancer.
van Engeland M, Roemen GM, Brink M, Pachen MM, Weijenberg MP, de Bruine AP, Arends JW, van den Brandt PA, de Goeij AF, Herman JG.
Oncogene 21(23):3792-5. 2002
67KRAS, RAC1, RAP1GDS1, RHOA
SmgGDS displays differential binding and exchange activity towards different Ras isoforms.
Vikis HG, Stewart S, Guan KL.
Oncogene 21(15):2425-32.PMID: 11948427 2002
68KRAS
Genotypic and phenotypic progression in endometrial tumorigenesis : determining when defects in DNA mismatch repair and KRAS2 occur.
Cohn DE, Mutch DG, Herzog TJ, Rader JS, Dintzis SM, Gersell DJ, Todd CR, Goodfellow PJ.
Genes Chromosomes Cancer 32 : 295-301. 2001
69KRAS, NRAS
High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.
Bezieau S, Devilder MC, Avet-Loiseau H, Mellerin MP, Puthier D, Pennarun E, Rapp MJ, Harousseau JL, Moisan JP, Bataille R.
Hum Mutat 18(3):212-24. 2001
70KRAS
The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers.
Konishi T, Huang CL, Adachi M, Taki T, Inufusa H, Kodama K, Kohno N, Miyake M.
Int J Oncol 16(3):501-11. 2000
71KRAS, TP53
Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability.
Swisher EM, et al.
Cancer 85(1):119-26. 1999
72KRAS
Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.
Graziano SL, et al.
J Clin Oncol 17(2):668-75. 1999
73BUB1, KRAS, MAD2L1
Mutational inactivation of mitotic checkpoint genes, hsMAD2 and hBUB1, is rare in sporadic digestive tract cancers.
Imai Y, Shiratori Y, Kato N, Inoue T, Omata M.
Jpn J Cancer Res 90(8):837-40 1999
74KRAS
Ki-ras codon 12 point mutation and p53 mutation in pancreatic diseases.
Yamaguchi K, Chijiiwa K, Noshiro H, Torata N, Kinoshita M, Tanaka M.
Hepatogastroenterology 46(28):2575-81 1999
75KRAS
A relationship between K-ras gene mutations and some clinical and histologic variables in patients with primary colorectal carcinoma.
Beranek M, Bures J, Palicka V, Jandik P, Langr F, Nejedla E.
Clin Chem Lab Med 37(7):723-7 1999
76KRAS
Specific K-ras2 mutations in human sporadic colorectal adenomas are associated with DNA near-diploid aneuploidy and inhibition of proliferation.
Giaretti W, et al.
Am J Pathol 153 : 1201-1209. 1998
77KRAS
Correlation of genetic instability and apoptosis in the presence of oncogenic Ki-Ras.
Chen CY, et al.
Cell Death Differ 5 : 984-995. 1998
78ITPR2, SSPN, KRAS
Coamplification in tumors of KRAS2, type 2 inositol 1,4,5 triphosphate receptor gene, and a novel human gene, KRAG.
Heighway J, et al.
Genomics 35 : 207-214. 1996
79KRAS
Studies on ras oncogene activation in endometrial carcinoma.
Fujimoto I, et al.
Gynecol Oncol 48 : 196-202. 1993
80KRAS
K-ras mutations in human adenocarcinoma of the lung : association with smoking and occupational exposure to asbestos.
Husgafvel-Pursiainen K, et al.
Int J Cancer 53 : 250-256. 1993
81NRAS, KRAS
Analysis of karyotype, SCE, and point mutation of RAS oncogene in Indian MDS patients.
Mansoor AM, et al.
Cancer Genet Cytogenet 65 : 12-20. 1993
82NRAS, KRAS
Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas.
Pergolizzi RG, et al.
Cancer Invest 11 : 25-32. 1993
83KRAS
Primitive neuroectodermal tumors after prophylatic central nervous system iradiation in children.
BrŸstle O, et al.
Cancer 69 : 2385-2392. 1992
84HRAS, KRAS, NRAS
Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas.
Challen C, et al.
J Hepatol 14 : 342-346. 1992
85KRAS
c-Ki-ras mutations in dysplastic fields and cancers in ulcerative colitis.
Chen J, et al.
Gastroenterology 102 : 1983-1987. 1992
86KRAS
Infrequent mutation of the ras genes in skin tumors of xeroderma pigmentosum patients in Japan.
Ishizaki K, et al.
Int J Cancer 50 : 382-385. 1992
87KRAS
Stability of K-ras mutations throughout the natural history of human colorectal cancer.
Losi L, et al.
Eur J Cancer 28A : 1115-1120. 1992
88KRAS
Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium.
Mizuuchi H, et al.
Cancer Res 52 : 2777-2781. 1992
89KRAS
Detection of K-ras mutations by denaturing gradient gel electrophoresis (DGGE) : a study on pancreatic cancer.
Pellegata NS, et al.
Anticancer Res 12 : 1731-1736. 1992
90NRAS, KRAS
Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia.
Nakagawa T, et al.
Oncology 49 : 114-122. 1992
91KRAS
A point mutation of C-KI-RAS gene was found in human esophageal carcinoma cell lines but not in primary esophageal carcinomas.
Shiga C, et al.
Biochem Biophys Res Commun 187 : 515-521. 1992
92KRAS
Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors.
Sidransky D, et al.
Science 256 : 102-104. 1992
93KRAS, NRAS
ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis.
Sugio K, et al.
Cancer Res 52 : 2903-2906. 1992
94KRAS
High incidence of ras gene mutation in intrahepatic cholangiocarcinoma.
Tada M, et al.
Cancer 69 : 1115-1118. 1992
95KRAS
Specific cytogenetic abnormalities and k-ras mutation in two new human colorectal-adenoma-derived cell lines.
Williams AC, et al.
Int J Cancer 52 : 785-790. 1992
96KRAS
Primers for detection of StuI and BstXI polymorphisms in a fragment co-amplified with c-Ki-ras 2 (KRAS2).
Heighway J.
Nucleic Acids Res 19 : 3162. 1991
97KRAS
PCR assay for a polymorphic TaqI site in the human K-ras-2 gene on chromosome 12p (KRAS2).
Abrams ES, et al.
Nucleic Acids Res 19 : 4795. 1991
98KRAS
DdeI polymorphism within sequence encoding 3' untranslated region of c-Ki-ras2 (KRAS2).
Heighway J.
Nucleic Acids Res 19 : 5092. 1991
99KRAS
PCR primers to convert c-Ki-ras to a four allele RsaI system (KRAS2).
Heighway J.
Nucleic Acids Res 19 : 6966. 1991
100KRAS
Higher frequency of point mutations in the c-K-ras 2 gene in human colorectal adenomas with severe atypia than in carcinomas.
Ando M, et al.
Jpn J Cancer Res 82 : 245-249. 1991
101KRAS
Point mutation of c-Ki-ras oncogene in gastric adenoma and adenocarcinoma with tubular differentiation.
Kihana T, et al.
Jpn J Cancer Res 82 : 308-314. 1991
102KRAS
Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique.
Levi S, et al.
Cancer Res 51 : 3497-3502. 1991
103KRAS
RsaI polymorphism in c-Ki-ras.
Heighway J.
Nucleic Acids Res 19 : 968. 1991
104KRAS
Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma.
Burmer GC, et al.
Proc Natl Acad Sci U S A 86 : 2403-2407. 1989
105KRAS
Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse.
You M, et al.
Proc Natl Acad Sci U S A 86 : 3070-3074. 1989
106HRAS, KRAS
Analysis of RAS oncogene mutations in human lymphoid malignancies.
Neri A, et al.
Proc Natl Acad Sci U S A 85 : 9268-9272. 1988
107KRAS1P, KRAS
Viral K-ras detects two Taqi polymorphisms, one for KRAS1 on chromosome 6 and the other for KRAS2 on chromosome 12.
Okamoto M, et al.
Nucleic Acids Res 16 : 2363. 1988
108KRAS
A new polymorphism at the KRAS locus and linkage with known KRAS polymorphisms.
Zuppan P, et al.
(HGM9) Cytogenet Cell Genet 46 : 727. 1987
109NRAS, KRAS1P, KRAS
Prevalence of ras gene mutations in human colorectal cancers.
Bos JL, et al.
Nature 327 : 293-297. 1987
110KRAS1P, KRAS
Detection of high incidence of K- ras oncogenes during human colon tumorigenesis.
Forrester K, et al.
Nature 327 : 298-303. 1987
111KRAS
An EcoRI restriction fragment length polymorphism at the KRAS2 locus on mouse chromosome 6.
Ryan J, et al.
Nucleic Acids Res 14 : 9222. 1986
112KRAS
c-K-ras Codon 12 GGT-GGT point mutation : an infrequent event in human lung cancer.
Milici A, et al.
Biochem Biophys Res Commun 140 : 699-705. 1986
113KRAS
Anonymous genomic fragment co-amplified with c-Ki-ras 2 detects frequent polymorphism (pK42).
Heighway J, et al.
Nucleic Acids Res 14 : 8700. 1986
114NRAS, KRAS
Chromosomal localization of three human ras genes by in situ molecularhybridization.
Popescu NC, et al.
Somat Cell Mol Genet 11 : 149-155. 1985
115KRAS1P, KRAS
Regional localization of two human cellular Kirsten ras genes on chromosomes 6 and 12.
Sakaguchi AY, et al.
Mol Cell Biol 4 : 989-993. 1984
116HRAS, ERAS, KRAS1P, KRAS
Dispersion of the ras family of transforming genes to four different chromosomes in man.
O'Brien SJ, et al.
Nature 302 : 839-842. 1983
117KRAS
Human c-Ki-ras2 proto-oncogene on chromosome 12.
Sakaguchi AY, et al.
Science 219 : 1081-1082. 1983
118KRAS1P, KRAS, NRAS
Regional chromosomal localization of N-ras, K-ras-1, Kras-2 and myb oncogenes in human cells.
McBride OW, et al.
Nucleic Acids Res 11 : 8221-8236. 1983